Date: 2015-04-21
Type of information: Private placement
Company: Sage Therapeutics (USA - MA)
Investors:
Amount: $138 million (€128.4 million)
Funding type: private placement
Planned used:
Others: * On April 21, 2015, Sage Therapeutics announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 342,857 shares at the public offering price of $52.50 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by SAGE to 2,628,571 shares and increased the amount of gross proceeds raised in the offering, before underwriting discounts and estimated expenses of the offering, to approximately $138 million. * On April 14, 2015, Sage Therapeutics announced the pricing of an underwritten public offering of 2,285,714 shares of its common stock at a public offering price of $52.50 per share, before underwriting discounts. In addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 342,857 shares of common stock on the same terms and conditions. J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Partners LLC and Cowen and Company, LLC are serving as co-managers. The offering is expected to close on or about April 20, 2015, subject to customary closing conditions. * On April 13, 2015, Sage Therapeutics announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares in the offering are to be sold by SAGE. SAGE intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Therapeutic area: CNS diseases - Neurological diseases
